Cogan Syndrome (Autoimmune/Immune‑mediated Vasculitis) — Disease Characteristics Research Report

Executive summary

Cogan syndrome (CS) is a rare immune‑mediated disorder classically defined by inflammatory ocular disease (especially non‑syphilitic interstitial keratitis) together with audiovestibular dysfunction (often Ménière‑like episodes and progressive sensorineural hearing loss), with frequent systemic vasculitic involvement that can include potentially life‑threatening aortitis. (wang2023cogan’ssyndromeis pages 1-2, espinoza2020cogan’ssyndromeclinical pages 1-3, tayershifman2014coganssyndrome—clinicalguidelines pages 2-3)

Recent clinically actionable findings include (i) continued emphasis that diagnosis is clinical and by exclusion, with no single confirmatory biomarker; (ii) increasing use of biologics (especially anti‑TNF agents such as infliximab) for steroid‑refractory disease; and (iii) early hearing rehabilitation (cochlear implantation) when profound hearing loss occurs due to risk of intracochlear fibrosis/neo‑ossification. (espinoza2020cogan’ssyndromeclinical pages 4-5, shamriz2018autoimmuneinnerear pages 1-2, rucklova2023paediatriccogan´ssyndrome pages 2-4)

1. Disease Information

1.1 Overview / definition

Core concept: CS is a “variable vessel vasculitis” phenotype with primary involvement of the eye and inner ear, and with systemic vasculitis in a substantial subset. (ince2023coganssyndrome pages 1-2, tayershifman2014coganssyndrome—clinicalguidelines pages 2-3)

Typical vs atypical CS (2‑year rule): - Typical CS is commonly defined by non‑syphilitic interstitial keratitis plus audiovestibular symptoms occurring within 2 years. (wang2023cogan’ssyndromeis pages 1-2) - Atypical CS includes (a) ocular inflammation other than interstitial keratitis and/or (b) >2‑year delay between ocular and audiovestibular manifestations, and is often described as more frequently systemic. (mendes2026atypicalcogan’ssyndrome pages 2-2, mendes2026atypicalcogan’ssyndrome pages 2-3)

Direct abstract quotes supporting definition: - “Cogan’s syndrome (CS) is a rare autoimmune disorder characterized by audiovestibular dysfunction and ocular inflammation.” (Shamriz 2018, published 2018-04-23; https://doi.org/10.1155/2018/1498640) (shamriz2018autoimmuneinnerear pages 1-2) - “Cogan´s syndrome is a rare, presumed autoimmune vasculitis of various vessels characterized by interstitial keratitis and vestibular impairment accompanied by sensorineural hearing loss.” (Rücklová 2023, published 2023-06; https://doi.org/10.1186/s12969-023-00830-x) (rucklova2023paediatriccogan´ssyndrome pages 2-4)

1.2 Key identifiers and controlled vocabulary

Note: In the evidence retrieved here, authoritative identifier mappings (e.g., MONDO, Orphanet ORPHA code, ICD‑10/ICD‑11, MeSH) were not directly available as primary sources. Therefore, IDs are not asserted in this report.

Synonyms / alternative names (used in clinical literature): - Cogan’s syndrome - Typical Cogan syndrome - Atypical Cogan syndrome - Cogan syndrome with aortitis / systemic vasculitis (wang2023cogan’ssyndromeis pages 1-2, tayershifman2014coganssyndrome—clinicalguidelines pages 2-3)

1.3 Evidence sources: individual vs aggregated

Because CS is rare, most treatment and phenotype evidence remains derived from case reports/series and retrospective cohorts, including systematic reviews that largely pool case reports. (marrerogonzalez2025audiovestibularoutcomesin pages 1-2, espinoza2020cogan’ssyndromeclinical pages 4-5)

2. Etiology

2.1 Disease causal factors (current understanding)

Primary etiology: CS is widely regarded as autoimmune/immune‑mediated with vasculitis as a key pathogenic mechanism. (espinoza2020cogan’ssyndromeclinical pages 1-3, greco2013coganssyndromean pages 2-3)

Immunologic evidence discussed in authoritative reviews includes: - Autoantibodies reported against corneal antigens, inner ear constituents, and endothelial antigens. (Greco 2013; https://doi.org/10.1016/j.autrev.2012.07.012) (greco2013coganssyndromean pages 2-3, greco2013coganssyndromean pages 1-2) - A proposed “Cogan peptide” with homology to CD148 (PTPRJ) and connexin 26 (GJB2), with reports that peptide‑specific antibodies can localize to the cochlea and transfer disease in animal models. (greco2013coganssyndromean pages 2-3)

Infectious/trigger hypotheses (non‑causal, indirect): Reviews discuss potential infection‑trigger models (e.g., viral triggers and molecular mimicry concepts), but evidence remains limited and non‑definitive. (tayershifman2014coganssyndrome—clinicalguidelines pages 1-2, tayershifman2014coganssyndrome—clinicalguidelines pages 2-3)

2.2 Risk factors

Robust population‑level risk factors are not established; epidemiology is rare and incidence is often described as unknown or not measurable due to the small number of cases. (ince2023coganssyndrome pages 1-2, tayershifman2014coganssyndrome—clinicalguidelines pages 1-2)

2.3 Protective factors

No validated protective genetic or environmental factors were identified in the retrieved evidence.

2.4 Gene–environment interactions

No validated gene–environment interaction data were identified in the retrieved evidence.

3. Phenotypes

3.1 Core phenotypic domains

CS phenotypes are commonly grouped as: 1) Ocular inflammatory disease (classically interstitial keratitis; also uveitis, episcleritis/scleritis, retinal vasculitis, etc.) (rucklova2023paediatriccogan´ssyndrome pages 2-4, tayershifman2014coganssyndrome—clinicalguidelines pages 2-3) 2) Audiovestibular disease (vertigo, tinnitus, nausea/vomiting, ataxia, progressive SNHL) (wang2023cogan’ssyndromeis pages 1-2, espinoza2020cogan’ssyndromeclinical pages 1-3) 3) Systemic vasculitis / inflammatory manifestations (fever, arthralgia, anemia, neurologic and gastrointestinal involvement; and aortitis) (wang2023cogan’ssyndromeis pages 1-2, wang2023cogan’ssyndromeis pages 2-5)

3.2 Phenotype characteristics with frequency (where available)

Pediatric case‑based aggregate (n=55; Rücklová 2023): - Ocular findings: 55/55 (100%) - Interstitial keratitis: 34/55 (62%) - Sensorineural hearing deficit: 55/55 (100%) - Vestibular symptoms: 37/54 (69%) - Any systemic symptoms: 32/55 (58%) - Aortitis: 9/55 (16%); 2/55 deaths reported (mortality 3.6%) (published 2023-06; https://doi.org/10.1186/s12969-023-00830-x) (rucklova2023paediatriccogan´ssyndrome pages 2-4)

HPO term suggestions (non‑exhaustive): - Interstitial keratitis — HP:0000496 (suggested) - Uveitis — HP:0000554 (suggested) - Scleritis / episcleritis — HP:0100537 / HP:0200042 (suggested) - Sensorineural hearing loss — HP:0000407 (suggested) - Vertigo — HP:0002321 (suggested) - Tinnitus — HP:0000360 (suggested) - Aortitis — HP:0004948 (suggested) - Fever — HP:0001945 (suggested) - Arthralgia — HP:0002829 (suggested)

3.3 Quality of life (QoL) impact

QoL is primarily affected by permanent or fluctuating hearing loss, vestibular dysfunction, and visual symptoms. A key clinical consequence emphasized in reviews is progression to irreversible bilateral profound SNHL in a substantial fraction of patients, driving cochlear implant candidacy. (shamriz2018autoimmuneinnerear pages 1-2, espinoza2020cogan’ssyndromeclinical pages 4-5)

4. Genetic/Molecular Information

4.1 Causal genes

No monogenic causal gene for CS is established in the retrieved evidence; CS is treated as an immune‑mediated syndrome rather than a Mendelian disorder. (tayershifman2014coganssyndrome—clinicalguidelines pages 1-2, shamriz2018autoimmuneinnerear pages 1-2)

4.2 Candidate autoantigens/biomarkers (not diagnostic)

Key points: No serum autoantibody is sufficiently validated for routine diagnosis. (shamriz2018autoimmuneinnerear pages 1-2)

• Anti‑HSP70 has been proposed in the context of autoimmune inner ear disease and studied in CS cohorts, with variable positivity across studies and higher positivity reported in typical CS in at least one cohort summarized by Shamriz et al. (2018). (shamriz2018autoimmuneinnerear pages 1-2)
• “Cogan peptide”/cross‑reactive targets (CD148/PTPRJ; connexin 26/GJB2) and endothelial antigen reactivity have been described in reviews. (greco2013coganssyndromean pages 2-3, tayershifman2014coganssyndrome—clinicalguidelines pages 1-2)
• Inflammatory markers (ESR/CRP) are commonly elevated during active disease; IL‑6 can be elevated and has been used as rationale for IL‑6 blockade in case reports/series contexts. (wang2023cogan’ssyndromeis pages 1-2, wang2023cogan’ssyndromeis pages 2-5)

CHEBI suggestions (where relevant): - Prednisone (CHEBI term exists) - Methylprednisolone (CHEBI term exists) - Methotrexate (CHEBI term exists) - Cyclophosphamide (CHEBI term exists) - Tocilizumab (biologic; CHEBI mapping may exist depending on ontology version)

4.3 Epigenetics / chromosomal abnormalities

No CS‑specific epigenetic or chromosomal abnormality evidence was identified in the retrieved sources.

5. Environmental Information

No validated environmental toxins, lifestyle factors, or specific infectious agents were established as causal in the retrieved evidence. Reviews discuss infectious trigger hypotheses but without definitive confirmation. (tayershifman2014coganssyndrome—clinicalguidelines pages 1-2, greco2013coganssyndromean pages 1-2)

6. Mechanism / Pathophysiology

6.1 Mechanistic model (causal chain)

Proposed upstream trigger(s): immune activation possibly triggered by infection or other exposures in a susceptible host (hypothesized). (tayershifman2014coganssyndrome—clinicalguidelines pages 1-2)

Core immune process: autoimmune/immune‑mediated inflammation with vasculitic injury affecting eye and inner ear; systemic manifestations arise when larger/variable vessels are involved (including the aorta). (greco2013coganssyndromean pages 2-3, tayershifman2014coganssyndrome—clinicalguidelines pages 2-3)

Downstream tissue injury and clinical manifestations: - Corneal/ocular inflammation → interstitial keratitis/uveitis/scleritis → pain, photophobia, blurred vision. (tayershifman2014coganssyndrome—clinicalguidelines pages 2-3, rucklova2023paediatriccogan´ssyndrome pages 2-4) - Inner ear inflammation/microvascular injury → cochleovestibular dysfunction → vertigo/tinnitus and progressive SNHL → potential irreversible deafness. (wang2023cogan’ssyndromeis pages 1-2, shamriz2018autoimmuneinnerear pages 1-2) - Large vessel vasculitis (aortitis) → aortic root/valvular dysfunction and vascular complications (aneurysm/stenosis) → morbidity/mortality risk. (wang2023cogan’ssyndromeis pages 1-2, espinoza2020cogan’ssyndromeclinical pages 4-5, tayershifman2014coganssyndrome—clinicalguidelines pages 2-3)

6.2 Pathways and cellular processes (ontology suggestions)

GO Biological Process (suggested): - GO:0006954 inflammatory response - GO:0002682 regulation of immune system process - GO:0006955 immune response - GO:0002526 acute inflammatory response - GO:0006952 defense response - GO:0050729 positive regulation of inflammatory response

CL Cell types (suggested, consistent with inflammatory vasculitis): - Macrophage — CL:0000235 - T cell — CL:0000084 - B cell / plasma cell — CL:0000236 / CL:0000786 - Vascular endothelial cell — CL:0000115

6.3 Molecular profiling (transcriptomics/proteomics/metabolomics)

No validated CS‑specific multi‑omics signatures were identified in the retrieved evidence.

7. Anatomical Structures Affected

7.1 Organ/system level (primary)

• Eye (cornea; uvea; sclera) (tayershifman2014coganssyndrome—clinicalguidelines pages 2-3, rucklova2023paediatriccogan´ssyndrome pages 2-4)
• Inner ear (cochlea; vestibular apparatus) (shamriz2018autoimmuneinnerear pages 1-2, rucklova2023paediatriccogan´ssyndrome pages 2-4)
• Large vessels, especially aorta (aortitis/aortic root involvement) (wang2023cogan’ssyndromeis pages 1-2, tayershifman2014coganssyndrome—clinicalguidelines pages 2-3)

UBERON suggestions: - Eye — UBERON:0000970 - Cornea — UBERON:0000964 - Inner ear — UBERON:0001845 - Cochlea — UBERON:0001846 - Aorta — UBERON:0000947

7.2 Tissue/cell level

Evidence supports inflammatory infiltration and vasculitic pathology in relevant tissues in some reports and reviews, consistent with immune‑mediated injury; definitive cell‑resolved mapping is not standardized. (greco2013coganssyndromean pages 4-4)

7.3 Subcellular level

No CS‑specific subcellular compartment pathology was identified.

8. Temporal Development

8.1 Onset and course

• Often described in young adults (20s–30s) but can occur in children and older adults. (wang2023cogan’ssyndromeis pages 1-2, shamriz2018autoimmuneinnerear pages 1-2)
• Course may be relapsing and evolve over years; early treatment is emphasized to limit irreversible hearing loss. (espinoza2020cogan’ssyndromeclinical pages 4-5)

Pediatric timing: pediatric literature review reports median age 12 years (range 3–18). (rucklova2023paediatriccogan´ssyndrome pages 2-4)

8.2 Typical vs atypical timing

• The “2‑year” separation is used to operationalize typical vs atypical disease, but some expert commentary suggests the distinction may be less important for long‑term management than prevention of disability and systemic complications. (espinoza2020cogan’ssyndromeclinical pages 4-5)

9. Inheritance and Population

9.1 Epidemiology

Population prevalence/incidence is not well defined in the retrieved sources.

Case‑count estimates and age/sex: - Reviews describe ~250 reported cases (2018 review) and “few hundred” cases since 1945. (shamriz2018autoimmuneinnerear pages 1-2, wang2023cogan’ssyndromeis pages 2-5) - One cohort summarized in Shamriz 2018: median onset 25 years (range 5–63) and no clear gender predominance. (shamriz2018autoimmuneinnerear pages 1-2) - Pediatric aggregation: male 31/54 (57%). (rucklova2023paediatriccogan´ssyndrome pages 2-4)

9.2 Inheritance

No Mendelian inheritance pattern is established; CS is treated as non‑Mendelian/immune‑mediated. (tayershifman2014coganssyndrome—clinicalguidelines pages 1-2, shamriz2018autoimmuneinnerear pages 1-2)

10. Diagnostics

10.1 Clinical criteria and diagnostic approach

Across reviews, CS diagnosis is clinical, requiring: 1) inflammatory ocular disease, 2) audiovestibular involvement (often rapidly progressing SNHL), and 3) exclusion of alternative causes, especially syphilis and other infectious/autoimmune mimics. (tayershifman2014coganssyndrome—clinicalguidelines pages 2-3, rucklova2023paediatriccogan´ssyndrome pages 2-4)

Direct quote (review text): “To date, since there is no specific test, the diagnosis of CS is based on clinical findings…” (Tayer‑Shifman 2014, published 2014-01; https://doi.org/10.1007/s12016-013-8406-7) (tayershifman2014coganssyndrome—clinicalguidelines pages 2-3)

10.2 Laboratory tests and biomarkers

• Inflammatory markers (ESR/CRP) are non‑specific but used to track disease activity. (wang2023cogan’ssyndromeis pages 1-2, rucklova2023paediatriccogan´ssyndrome pages 2-4)
• No single serum autoantibody is accepted for routine diagnostic workup. (shamriz2018autoimmuneinnerear pages 1-2)
• Workup frequently includes broad autoimmune serologies (ANA/ANCA/RF etc.) primarily to evaluate alternative diagnoses; positivity in larger CS studies is generally low per reviews. (shamriz2018autoimmuneinnerear pages 1-2, marrerogonzalez2025audiovestibularoutcomesin pages 2-4)

10.3 Imaging and functional testing

• Audiometry (pure tone audiogram) for quantification and follow‑up of SNHL. (tayershifman2014coganssyndrome—clinicalguidelines pages 2-3)
• CT/MRI head/inner ear to exclude other causes; MRI may show labyrinthitis or other inner ear changes though can be normal. (espinoza2020cogan’ssyndromeclinical pages 1-3, marrerogonzalez2025audiovestibularoutcomesin pages 2-4)
• Echocardiography is emphasized for aortitis/aortic valvular dysfunction assessment once CS suspected/diagnosed. (tayershifman2014coganssyndrome—clinicalguidelines pages 2-3, wang2023cogan’ssyndromeis pages 2-5)
• FDG‑PET/CT has been used/recommended in selected cases to detect aortitis or inflammatory activity (investigational/adjunct). (espinoza2020cogan’ssyndromeclinical pages 4-5, tayershifman2014coganssyndrome—clinicalguidelines pages 2-3)

10.4 Differential diagnosis (examples from pediatric diagnostic table)

Important exclusions include syphilis, tuberculosis, chlamydia, sarcoidosis, PAN, ANCA‑associated vasculitides, Behçet disease, Takayasu arteritis, Vogt‑Koyanagi‑Harada syndrome, Susac syndrome, and connective tissue disorders. (rucklova2023paediatriccogan´ssyndrome pages 2-4)

10.5 Genetic testing

Genetic testing is not a standard diagnostic tool for CS based on the retrieved evidence (no established causal gene). (tayershifman2014coganssyndrome—clinicalguidelines pages 1-2)

11. Outcome / Prognosis

11.1 Hearing and visual outcomes

• Hearing loss may progress to irreversible bilateral profound SNHL in approximately half of patients in at least one review. (shamriz2018autoimmuneinnerear pages 1-2)
• A 2023 literature review states “Nearly 43% develop deafness” and “blindness has been reported in 8%.” (Wang 2023, published 2023-05; https://doi.org/10.1186/s12886-023-02966-6) (wang2023cogan’ssyndromeis pages 1-2)

11.2 Systemic vasculitis complications

Systemic involvement is common in some series/reviews (often cited up to ~80%), with aortitis around ~10% in multiple reviews and higher rates in pediatric aggregation. (espinoza2020cogan’ssyndromeclinical pages 1-3, tayershifman2014coganssyndrome—clinicalguidelines pages 2-3, rucklova2023paediatriccogan´ssyndrome pages 2-4)

12. Treatment

12.1 Pharmacotherapy (current standard and escalation)

First‑line: high‑dose systemic corticosteroids for acute/active disease, with topical ocular steroids for mild ocular disease. (espinoza2020cogan’ssyndromeclinical pages 4-5, tayershifman2014coganssyndrome—clinicalguidelines pages 2-3)

Timing matters for hearing: high‑dose steroids given within ~2 weeks of auditory symptom onset improve odds of hearing recovery. (espinoza2020cogan’ssyndromeclinical pages 4-5)

Steroid‑sparing csDMARDs (examples): methotrexate, azathioprine, cyclosporine, mycophenolate mofetil; cyclophosphamide for severe systemic vasculitis. (mendes2026atypicalcogan’ssyndrome pages 2-3, tayershifman2014coganssyndrome—clinicalguidelines pages 2-3, marrerogonzalez2025audiovestibularoutcomesin pages 2-4)

Biologics (refractory disease): anti‑TNF agents are most frequently emphasized; infliximab is highlighted as a leading option in multiple reviews. (espinoza2020cogan’ssyndromeclinical pages 4-5, tayershifman2014coganssyndrome—clinicalguidelines pages 1-2)

Quantitative outcomes from treatment literature (selected): - Infliximab: 80% response rate at 6 months for vestibuloauditory symptoms in a treatment review summary. (Espinoza 2020, published 2020-06; https://doi.org/10.1007/s11882-020-00945-1) (espinoza2020cogan’ssyndromeclinical pages 4-5) - Adult systematic review of case reports (n=79): 60% treated only with oral steroids had no audiologic improvement, while 85.7% treated with biologic DMARDs improved audiologically. (Marrero‑Gonzalez 2025; https://doi.org/10.1007/s00405-024-08878-5) (marrerogonzalez2025audiovestibularoutcomesin pages 1-2)

Newer/experimental approaches noted in recent reports: - IL‑6 blockade (tocilizumab) used in refractory cases; elevated IL‑6 reported in some cases and normalization of inflammatory markers after tocilizumab reported in case‑based narratives. (wang2023cogan’ssyndromeis pages 2-5) - JAK inhibitors (e.g., tofacitinib) used in selected refractory cases for systemic/joint manifestations (hearing stabilization variable). (wang2023cogan’ssyndromeis pages 1-2)

12.2 Surgical and interventional

Cochlear implantation (CI): - CI is recommended early in profound SNHL because inflammatory inner ear disease can cause intracochlear fibrosis/neo‑ossification, complicating later implantation. (shamriz2018autoimmuneinnerear pages 1-2) - Pediatric case‑based report describes evaluation for unilateral CI after one ear remained deaf despite immunomodulatory therapy; MRI resolution of inflammation raised concern for intracochlear fibrosis, “emphasiz[ing] the urgency of CI.” (rucklova2023paediatriccogan´ssyndrome pages 2-4)

12.3 MAXO term suggestions (selected)

• Systemic glucocorticoid therapy — MAXO term exists (suggested)
• Immunosuppressive therapy — MAXO term exists (suggested)
• Tumor necrosis factor inhibitor therapy — MAXO term exists (suggested)
• Cochlear implantation — MAXO term exists (suggested)
• Echocardiography (for surveillance) — MAXO term exists (suggested)

12.4 Clinical trials

No CS‑specific interventional trials were identified in the retrieved ClinicalTrials.gov search results; current evidence base is dominated by observational data, case series, and case reports. (Evidence state: no relevant clinical trials retrieved)

13. Prevention

No established primary prevention strategy exists. Practical prevention is largely tertiary prevention: early recognition and immunosuppression to prevent irreversible SNHL and monitoring for aortitis/vascular complications. (espinoza2020cogan’ssyndromeclinical pages 4-5, tayershifman2014coganssyndrome—clinicalguidelines pages 2-3)

14. Other Species / Natural Disease

No naturally occurring CS equivalent in non‑human species was identified in the retrieved evidence.

15. Model Organisms

No standardized model organism resource or widely used experimental model for CS was identified in the retrieved evidence; however, immune reactivity to candidate antigens (“Cogan peptide”) and disease transfer/induction has been discussed in reviews, implying experimental work exists but is not established as a canonical model system. (greco2013coganssyndromean pages 2-3)

Key quantitative/clinical facts table

Table: This table compiles the most actionable quantitative and definitional findings for Cogan syndrome from the retrieved evidence. It highlights diagnostic distinctions, pediatric and adult cohort statistics, and treatment/outcome figures useful for rapid knowledge-base entry.

Expert opinion / authoritative analysis (synthesis)

1) Diagnosis remains syndromic and exclusionary: multiple authoritative reviews emphasize there is no specific diagnostic test, and evaluation must exclude infections (syphilis, TB) and systemic inflammatory mimics while assessing for vasculitis (including echocardiographic screening for aortitis). (tayershifman2014coganssyndrome—clinicalguidelines pages 2-3, rucklova2023paediatriccogan´ssyndrome pages 2-4) 2) Early immunosuppression is time‑critical for hearing: steroid treatment in the first ~2 weeks of auditory symptom onset is repeatedly highlighted as improving hearing recovery odds, but many patients still progress to profound SNHL. (espinoza2020cogan’ssyndromeclinical pages 4-5, shamriz2018autoimmuneinnerear pages 1-2) 3) Biologic therapy is increasingly used in refractory disease: anti‑TNF therapy (especially infliximab) is the most consistently emphasized biologic across reviews, with aggregated evidence suggesting improved vestibuloauditory outcomes compared with steroids alone in case‑based evidence. (espinoza2020cogan’ssyndromeclinical pages 4-5, marrerogonzalez2025audiovestibularoutcomesin pages 1-2)

Limitations of this report

• Authoritative disease identifier mappings (MONDO/Orphanet/ICD/MeSH) were not retrievable from the provided evidence set, so identifiers are not asserted.
• Many “latest developments” in 2023–2024 are case‑based; high‑quality randomized trials remain scarce or absent in the retrieved evidence, limiting certainty for comparative efficacy claims.

References

1. (wang2023cogan’ssyndromeis pages 1-2): Yanqing Wang, Shichao Tang, Chong Shao, and Yu Liu. Cogan’s syndrome is more than just keratitis: a case-based literature review. BMC Ophthalmology, May 2023. URL: https://doi.org/10.1186/s12886-023-02966-6, doi:10.1186/s12886-023-02966-6. This article has 12 citations and is from a peer-reviewed journal.

2. (espinoza2020cogan’ssyndromeclinical pages 1-3): Gabriela Mabel Espinoza, Joseph Wheeler, Katherine K. Temprano, and Angela Prost Keller. Cogan’s syndrome: clinical presentations and update on treatment. Current Allergy and Asthma Reports, 20:1-6, Jun 2020. URL: https://doi.org/10.1007/s11882-020-00945-1, doi:10.1007/s11882-020-00945-1. This article has 69 citations and is from a peer-reviewed journal.

3. (tayershifman2014coganssyndrome—clinicalguidelines pages 2-3): Oshrat E. Tayer-Shifman, Ophir Ilan, Hodaya Tovi, and Yuval Tal. Cogan's syndrome—clinical guidelines and novel therapeutic approaches. Clinical Reviews in Allergy & Immunology, 47:65-72, Jan 2014. URL: https://doi.org/10.1007/s12016-013-8406-7, doi:10.1007/s12016-013-8406-7. This article has 73 citations and is from a peer-reviewed journal.

4. (espinoza2020cogan’ssyndromeclinical pages 4-5): Gabriela Mabel Espinoza, Joseph Wheeler, Katherine K. Temprano, and Angela Prost Keller. Cogan’s syndrome: clinical presentations and update on treatment. Current Allergy and Asthma Reports, 20:1-6, Jun 2020. URL: https://doi.org/10.1007/s11882-020-00945-1, doi:10.1007/s11882-020-00945-1. This article has 69 citations and is from a peer-reviewed journal.

5. (shamriz2018autoimmuneinnerear pages 1-2): Oded Shamriz, Yuval Tal, and Menachem Gross. Autoimmune inner ear disease: immune biomarkers, audiovestibular aspects, and therapeutic modalities of cogan's syndrome. Journal of Immunology Research, 2018:1-8, Apr 2018. URL: https://doi.org/10.1155/2018/1498640, doi:10.1155/2018/1498640. This article has 52 citations and is from a peer-reviewed journal.

6. (rucklova2023paediatriccogan´ssyndrome pages 2-4): Kristina Rücklová, Thekla von Kalle, Assen Koitschev, Katrin Gekeler, Miriam Scheltdorf, Anita Heinkele, Friederike Blankenburg, Ina Kötter, and Anton Hospach. Paediatric cogan´s syndrome - review of literature, case report and practical approach to diagnosis and management. Pediatric Rheumatology Online Journal, Jun 2023. URL: https://doi.org/10.1186/s12969-023-00830-x, doi:10.1186/s12969-023-00830-x. This article has 7 citations.

7. (ince2023coganssyndrome pages 1-2): B İnce and S Kamalı. Cogan's syndrome. Unknown journal, 2023.

8. (mendes2026atypicalcogan’ssyndrome pages 2-2): João Mendes, Francisco Mendes, Diogo Valente Fortunato, João Vasco Garrido, Rita Condesso, and Augusto Candeias. Atypical cogan’s syndrome presenting as anterior scleritis: case report. Case Reports in Ophthalmology, 17:371-379, Mar 2026. URL: https://doi.org/10.1159/000551227, doi:10.1159/000551227. This article has 0 citations and is from a peer-reviewed journal.

9. (mendes2026atypicalcogan’ssyndrome pages 2-3): João Mendes, Francisco Mendes, Diogo Valente Fortunato, João Vasco Garrido, Rita Condesso, and Augusto Candeias. Atypical cogan’s syndrome presenting as anterior scleritis: case report. Case Reports in Ophthalmology, 17:371-379, Mar 2026. URL: https://doi.org/10.1159/000551227, doi:10.1159/000551227. This article has 0 citations and is from a peer-reviewed journal.

10. (marrerogonzalez2025audiovestibularoutcomesin pages 1-2): Alejandro R. Marrero-Gonzalez, Celine Ward, Shaun A. Nguyen, Seth S. Jeong, and Habib G. Rizk. Audiovestibular outcomes in adult patients with cogan syndrome: a systematic review. European Archives of Oto-Rhino-Laryngology, 282:23-35, Aug 2025. URL: https://doi.org/10.1007/s00405-024-08878-5, doi:10.1007/s00405-024-08878-5. This article has 6 citations and is from a peer-reviewed journal.

11. (greco2013coganssyndromean pages 2-3): A. Greco, A. Gallo, M. Fusconi, G. Magliulo, R. Turchetta, C. Marinelli, G.F. Macri, A. De Virgilio, and M. de Vincentiis. Cogan's syndrome: an autoimmune inner ear disease. Autoimmunity reviews, 12 3:396-400, Jan 2013. URL: https://doi.org/10.1016/j.autrev.2012.07.012, doi:10.1016/j.autrev.2012.07.012. This article has 160 citations and is from a peer-reviewed journal.

12. (greco2013coganssyndromean pages 1-2): A. Greco, A. Gallo, M. Fusconi, G. Magliulo, R. Turchetta, C. Marinelli, G.F. Macri, A. De Virgilio, and M. de Vincentiis. Cogan's syndrome: an autoimmune inner ear disease. Autoimmunity reviews, 12 3:396-400, Jan 2013. URL: https://doi.org/10.1016/j.autrev.2012.07.012, doi:10.1016/j.autrev.2012.07.012. This article has 160 citations and is from a peer-reviewed journal.

13. (tayershifman2014coganssyndrome—clinicalguidelines pages 1-2): Oshrat E. Tayer-Shifman, Ophir Ilan, Hodaya Tovi, and Yuval Tal. Cogan's syndrome—clinical guidelines and novel therapeutic approaches. Clinical Reviews in Allergy & Immunology, 47:65-72, Jan 2014. URL: https://doi.org/10.1007/s12016-013-8406-7, doi:10.1007/s12016-013-8406-7. This article has 73 citations and is from a peer-reviewed journal.

14. (wang2023cogan’ssyndromeis pages 2-5): Yanqing Wang, Shichao Tang, Chong Shao, and Yu Liu. Cogan’s syndrome is more than just keratitis: a case-based literature review. BMC Ophthalmology, May 2023. URL: https://doi.org/10.1186/s12886-023-02966-6, doi:10.1186/s12886-023-02966-6. This article has 12 citations and is from a peer-reviewed journal.

15. (greco2013coganssyndromean pages 4-4): A. Greco, A. Gallo, M. Fusconi, G. Magliulo, R. Turchetta, C. Marinelli, G.F. Macri, A. De Virgilio, and M. de Vincentiis. Cogan's syndrome: an autoimmune inner ear disease. Autoimmunity reviews, 12 3:396-400, Jan 2013. URL: https://doi.org/10.1016/j.autrev.2012.07.012, doi:10.1016/j.autrev.2012.07.012. This article has 160 citations and is from a peer-reviewed journal.

16. (marrerogonzalez2025audiovestibularoutcomesin pages 2-4): Alejandro R. Marrero-Gonzalez, Celine Ward, Shaun A. Nguyen, Seth S. Jeong, and Habib G. Rizk. Audiovestibular outcomes in adult patients with cogan syndrome: a systematic review. European Archives of Oto-Rhino-Laryngology, 282:23-35, Aug 2025. URL: https://doi.org/10.1007/s00405-024-08878-5, doi:10.1007/s00405-024-08878-5. This article has 6 citations and is from a peer-reviewed journal.